Recon: Astellas drops lawsuit over Medicare pricing negotiations; Pfizer, Valneva see positive results in Lyme vaccine booster study

• Astellas withdraws lawsuit after evading Medicare drug price negotiations (STAT) (Reuters)
• Why the drug industry’s opaque warnings on price negotiations fall short (STAT)
• What could fix cancer clinical trials’ longstanding diversity problem? (STAT)
• Pfizer, Valneva say 'positive' result for Lyme disease vaccine candidate booster (Reuters)
• ANDA Submissions Lagging As FY 2023 Nears Its End (Pink Sheet)
• J&J shutters PhIII trial for pulmonary hypertension drug, blocking its expanded use as patent expiry looms (Endpoints)
• FDA Rejects AstraZeneca’s Ultomiris Label Expansion in NMOSD (BioSpace)
• Moderna Says Updated COVID-19 Vaccine is Effective Against Newer Variants (BioSpace)

• South Africa was forced into ‘one-sided’ deals with Covid-19 vaccine suppliers, contracts reveal (STAT)
• Britain's Superdrug says Wegovy received is "very small fraction" of waiting list (Reuters)
• In boon for scientists, U.K. strikes deal to join E.U. Horizon research program (STAT)
• UK Considers US -Style Payment Reporting Obligations For Pharma Firms (Pink Sheet)
• EU Health Data Access Proposal Should Not Include Opt-Out Model, Pharma Says (Pink Sheet)
• Bristol Myers Squibb’s Camzyos gets NICE recommendation (Pharma Times)
• EC Plans New Structures For Manufacturers Of High-Risk IVDs Soon (MedTech Insight)

• Biogen names Jane Grogan as head of research (The Pharma Letter)
• Novo Nordisk teams up with Harvard, Broad Institute on diabetes and cardiac fibrosis (Fierce Biotech)
• Former Google AI expert raises $100mn for biotech start-up (Financial Times)
• FDA Sort-of Commits to Meet with Generic Drug Manufacturers that Have Received Warning Letters (FDA Law Blog)
• Cancer care appears brighter as off-the-shelf CAR-T advances (STAT)
• AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem (STAT)
• What a viral study criticizing cancer screening gets very, very wrong (STAT)
• Insulet shares slump on concerns of sales hit from new diabetes drugs (Reuters)
• Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial (Reuters)
  Seagen teams up with protein degradation specialist to make a new kind of antibody conjugate, paying $60M upfront (Endpoints)
• Ultra-Rare Tumors: Public-Private Partnership Eyed To Boost Drug Development (Pink Sheet)
• Ariceum doses first patient with satoreotide (Pharma Times)
• Neuroplast spinal cord injury study milestone (Pharma Times)
• Abbott Buys Bigfoot Biomedical – But What Lurks In The Forest? (MedTech Insight)
• Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win (BioSpace)
• BMS Accused by HMO of Patent Fraud to Allegedly Sustain Pomalyst Monopoly (BioSpace)
• Feeder Programs First Step in Bringing More Diversity to Pharma (BioSpace)
• Nimbus Secures $210M in Private Funding on Heels of $4B Takeda Deal (BioSpace)

• IBM notifies J&J unit Janssen CarePath's customers of unauthorized data access (Reuters)
• Philips settles one category of U.S. claims over respirator recall (Reuters)
• Synchron brain-computer interface implanted in first 6 US patients (MedTech Dive)
• Cue Health board pressured by investor to review strategy, cut costs (MedTech Dive)
• Vitestro begins blood-drawing device study (Pharma Times)
• Medtronic Faces Class-Action Lawsuit Over Alleged Patient Data Sharing From MiniMed, InPen Diabetes Devices (MedTech Insight)

• In Case You Missed It: News On Consent Decrees, Medicare’s ‘Small Biotech Exception’ And More (Pink Sheet)
• HHS’ Recommendation to Reschedule Cannabis to Schedule III Raises Questions (FDA Law Blog)